Search

everythinglearnresearchcommunity

for

Search:↓

The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Blocking the prolactin receptor might help treat various diseases, but more research is needed.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.

Gene therapy shows promise for treating skin disorders and cancer, but faces technical challenges.

New effective scar treatments are urgently needed due to the current options' limited success.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.

Targeted cancer therapies often cause serious skin problems that need careful management.

Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

The Wnt/β-catenin pathway helps tissue regeneration but can also cause fibrosis, and drugs that inhibit this pathway may aid in healing skin and heart tissues.

Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.

Stem cell therapies show promise for treating various diseases but face challenges in clinical use and require better monitoring techniques.

Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

In September 2016, there were major advancements and promising clinical trials in stem cell research and regenerative medicine.